Turkish Abstract Abstract Free Full Text English Similar Articles Mail to Author

¹MD, Assoc. Prof. Ophthalmology Department, Dokuz Eylul University School of Medicine, Balcova, Izmir, Turkey
²MD,Ophthalmologist,Internal Medicine, Rheumatology Department, Dokuz Eylul University School of Medicine, Balcova, Izmir, Turkey
³MD, Ophthalmologist, Ophthalmology Department, Dokuz Eylul University School of Medicine, Balcova, Izmir, Turkey
⁴MD, Ophthalmologist,Internal Medicine, Medical Oncology Department,Dokuz Eylul University School of Medicine, Balcova, Izmir, Turkey
⁵MD, Prof., Internal Medicine, Rheumatology Department, Dokuz Eylul University School of Medicine, Balcova, Izmir, Turkey
⁶MD, Prof.,Ophthalmology Department, Dokuz Eylul University School of Medicine, Balcova, Izmir, Turkey DOI : 10.37845/ret.vit.2020.29.62 Nivolumab is one of the new generation anti-cancer drugs used in the treatment of metastatic malignant melanoma, which acts by stimulating the immune system. Unilateral panuveitis was diagnosed in the left eye of 45 years-old man who was on nivolumab treatment for metastatic cutaneous malignant melanoma and presented with anterior uveitis, vitritis and macular edema. Nivolumab treatment was discontinued and two intravitreal dexamethasone implants were administered to left eye 4-months interval. The signs and symptoms were improved within 6 months of follow-up. We aimed to emphasize the need for the careful review of systemic disease history and the drugs used in patients diagnosed with uveitis and to increase awareness of clinicians regarding potential ocular side effects of new generation anti-cancer drugs. Keywords : Dexamethasone implant, Nivolumab, Panuveitis